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ABSTRACT Methicillin (-lactam) resistance in Staphylococcus epidermidis is medi-
ated by the mecA gene, with resistance reported to be as high as 90%. The goal of
this study was to evaluate oxacillin and cefoxitin disk diffusion (DD) and broth mi-
crodilution (BMD) methods for the detection of mecA-mediated -lactam resistance
in 100 human isolates of S. epidermidis (48 mecA-positive isolates and 52 mecA nega-
tive isolates). Oxacillin DD tests using the Clinical and Laboratory Standards Institute
(CLSI) M100-S28 breakpoints for S. pseudintermedius/S. schleiferi accurately differenti-
ated mecA-positive and -negative S. epidermidis isolates, with categorical agreement
(CA) of 100% and no very major errors (VMEs) or major errors (MEs) identified. Like-
wise, oxacillin BMD and cefoxitin DD tests using the coagulase-negative Staphylococ-
cus species (CoNS) breakpoints were highly reliable for detecting mecA-mediated
-lactam resistance in S. epidermidis isolates. For cefoxitin DD and BMD results inter-
preted using S. aureus/S. lugdunensis breakpoints, the CA was 97.6% and 96.2%, re-
spectively. There were 4.9% VMEs for cefoxitin DD with 0% MEs, and 3.6% VMEs and
3.9% MEs for cefoxitin BMD. Oxacillin BMD using S. aureus/S. lugdunensis breakpoints
yielded the highest VMEs at 17.4% and 90% CA. Our findings demonstrate that oxa-
cillin DD tests using the CLSI M100-S28 breakpoints for S. pseudintermedius/S. schleif-
eri and oxacillin BMD and cefoxitin DD tests using the CoNS breakpoints reliably
identified mecA-mediated -lactam resistance in S. epidermidis. Using mecA PCR as
the gold standard, the PBP2a SA culture colony test (Abbott Diagnostics) exhibited
100% sensitivity and specificity whereas 2 false negatives were identified using the
PBP2= latex agglutination test kit (Thermo Fisher Scientific) with sensitivity and speci-
ficity of 95.8% and 100%, respectively.
KEYWORDS broth microdilution, cefoxitin, disk diffusion, mecA, methicillin-resistant
Staphylococcus epidermidis, MIC, oxacillin, PBP2a, Staphylococcus epidermidis
Coagulase-negative Staphylococcus species (CoNS) represent major nosocomialpathogens commonly associated with infections related to indwelling devices and
implantation of foreign materials (1). Immunocompromised patients and premature
neonates are particularly vulnerable to infections caused by CoNS (1). Staphylococcus
epidermidis is the most common CoNS recovered from clinical sources and is found
ubiquitously on healthy human skin and mucous membranes (2). This species is also a
common cause of infections associated with prosthetic vascular grafts, prosthetic
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orthopedic devices (3), and cerebrospinal fluid (CSF) shunts (4). Furthermore, S. epider-
midis is capable of proliferating on the surfaces of indwelling devices to form biofilms
which are inherently more refractory to antimicrobial therapy, resulting in frequent
relapse following treatment (5).
Antimicrobial resistance is extremely common in S. epidermidis (1), and the species
often exhibits resistance to -lactams, rifampin, erythromycin, clindamycin, fluoro-
quinolones, and trimethoprim-sulfamethoxazole (6). Methicillin (-lactam) resistance in
S. epidermidis is mediated by the mecA gene, and the prevalence of methicillin-resistant
S. epidermidis (MRSE) has been reported to be as high as 90% (7).
Given the importance of accurate classification of methicillin resistance status, with
the continued adoption of new technologies (e.g., matrix-assisted laser desorption
ionization–time of flight mass spectrometry [MALDI-TOF MS]) by clinical laboratories
that allow improved identification of staphylococci to the species level, there is a need
to critically evaluate the best methods for detecting mecA-mediated oxacillin resistance
in specific species of CoNS. The CLSI Staphylococcus Ad Hoc Working Group previously
assessed the performance of phenotypic testing options for prediction of mecA-
mediated oxacillin resistance in Staphylococcus pseudintermedius and Staphylococcus
schleiferi (8, 9). This led to the discontinuation of cefoxitin disk diffusion (DD) testing
and inclusion of oxacillin DD testing as an option for detecting mecA-mediated resis-
tance in these species. Changes to the breakpoints were published in Clinical and
Laboratory Standards Institute (CLSI) documents M100-S27 and M100-S28, respectively.
These findings prompted further evaluation of other Staphylococcus species to deter-
mine whether the CLSI M100-S28 cefoxitin DD and oxacillin broth microdilution (BMD)
recommendations for other species are accurate, as supporting data for current cefoxi-
tin DD methodology were primarily derived from a small subset of S. epidermidis
isolates (10).
Here, we present data from a study evaluating oxacillin and cefoxitin DD and BMD
testing for detection of -lactam resistance in 100 human isolates of S. epidermidis (48
mecA positive, 52 mecA negative).
(The findings from this study were presented to the CLSI Antimicrobial Susceptibility
Testing Subcommittee in June 2018.)
MATERIALS AND METHODS
Bacterial isolates. A total of 100 human S. epidermidis isolates collected between 2015 and 2018
were included in this study (Table 1). Only one isolate per human subject was collected. Isolates were
recovered primarily from positive-testing blood culture broths but were also obtained from cultures of
other sterile sites (e.g., cerebrospinal and synovial fluids). Isolates were collected from the following 3
distinct geographical locations in the United States: NewYork-Presbyterian Hospital/Weill Cornell Medical
Center (WCMC), New York, NY (n  38); Barnes-Jewish Hospital (BJH), St. Louis, MO (n  22); and
Children’s Hospital Los Angeles (CHLA), Los Angeles, CA (n  40). Isolates were identified to the species
level during routine clinical testing with either the Verigene Gram-positive blood culture test (Luminex
Corporation, Austin, TX) or MALDI-TOF MS (Bruker Daltonics, Inc., Billerica, MA).
Detection of mecA. One hundred isolates were selected for nearly equal representation of mecA-
positive and -negative isolates (Table 1). Isolates were evaluated for the presence of the mecA gene as
part of routine clinical testing. At 2 sites (CHLA and WCMC), a positive blood culture broth demonstrating
Gram-positive cocci upon Gram stain analysis was assayed on the Verigene Gram-positive blood culture











CHLA 2016–2018 22 18 Arterial line, catheter, peripheral blood
BJMC 2015, 2017 10 12 Blood, CSF, joint fluid, synovial fluid
WCMC 2016–2017 20 18 Peripheral blood, catheter
Total 52 48
aBJMC, Barnes-Jewish Medical Center, St. Louis, MO; CHLA, Children’s Hospital Los Angeles, Los Angeles, CA;
CSF, cerebrospinal fluid; WCMC, New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY.
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panel per the manufacturer’s protocol. The panel has the ability to identify S. epidermidis and to detect
the mecA gene. At 1 site (BJH), S. epidermidis isolates were first assayed for susceptibility to -lactam
antibiotics by phenotypic means following CLSI methods (M07-A10 and M02-A12), and the BJH isolates
only were further interrogated for mecA using the Verigene Gram-positive blood culture test using a 0.5
McFarland in saline solution prepared from fresh isolates, followed by addition of 350 l of the
suspension to the sample well of the extraction tray. This additional testing of the isolates from BJH was
conducted at WCMC.
Antimicrobial susceptibility testing (AST). All isolates were shipped to 1 site (CHLA) for AST testing.
Testing was conducted in 10 batches. For each batch, 10 S. epidermidis isolates and an associated S.
aureus quality control (QC) isolate were tested. All isolates were stored at – 80°C and subcultured twice
on tryptic soy agar with 5% sheep blood agar plates (BAP) before testing.
Susceptibility to -lactams was interrogated by DD using 1 g oxacillin and 30 g cefoxitin disks
(Becton, Dickinson and Company [BD], Franklin Lakes, NJ) per CLSI recommendations (M012-A12).
Staphylococcus aureus ATCC 25923 was utilized as QC for each batch of 10 isolates, resulting in the
generation of 10 QC points. Mueller-Hinton agar (MHA) plates from Remel (Thermo Fisher Scientific,
Lenexa, KS), Hardy Diagnostics (Santa Maria, CA), and BD were tested. Colonies were resuspended in
0.85% saline solution as described above and inoculated onto MHA plates within 15 min with a sterile
cotton-tipped swab. Plates were allowed to dry for 3 to 5 min but for no longer than 15 min. MHA plates
were incubated at 35 to 37°C in ambient air, and zones of inhibition were measured at 16 to 18 h for
oxacillin and 24 h for cefoxitin. Both the oxacillin and cefoxitin zones of inhibition were read using
reflected light.
Susceptibility to -lactams was determined by BMD using oxacillin and cefoxitin per CLSI recom-
mendations (M07-A10). Custom BMD panels were prepared by Thermo Fisher Scientific. Each 96-well tray
consisted of six doubling dilution series such that oxacillin and cefoxitin were diluted in doubling
dilutions from 32 g/ml to 0.015 g/ml using independent cation-adjusted Mueller-Hinton broth (CA-
MHB) from three manufacturers: BBL (BD), Oxoid (Thermo Fisher Scientific), and Difco (Thermo Fisher
Scientific). BMD plates were frozen after manufacture and stored at 80°C until use. On the day of setup,
BMD trays were thawed for no longer than 60 min at room temperature in a single layer. S. aureus ATCC
29213 was utilized as the QC for each series of 10 experimental isolates, resulting in the generation of
10 QC points. Staphylococcus epidermidis colonies were resuspended in 0.85% saline solution (Hardy)
using sterile cotton-tipped swabs with wooden shafts (and were adjusted to 0.5 McFarland using a
Siemens turbidity meter, which translates to a reading of 0.06 to 0.10). The 0.5 McFarland suspension was
subjected to vortex mixing, after which 1 ml was pipetted into tubes of 29 ml demineralized water
without Tween (Thermo Fisher Scientific). This dilution was mixed by inverting the tube 3 to 5 times and
was then poured into the inoculator tray of an inoculator assembly (Thermo Fisher Scientific), which was
used to individually inoculate each BMD plate. A purity check was performed for each by sampling 1 l
from the inoculator tray or growth control well of the plate and plating on a BAP. Colony counts were
determined on the 5th and 10th isolate as well as the QC control of each experimental set as follows: a
10 l aliquot was taken from the growth control well immediately after inoculation and diluted in 5 ml
of 0.85% saline solution. After mixing, a 50-l volume was inoculated onto the surface of a blood agar
plate and spread evenly with a sterile loop, in duplicate. Plates were incubated at 35 to 37°C overnight.
Following incubation, the colonies on each of the two plates were counted and averaged. The average
colony count was multiplied by 10,000 to determine the total CFU count per milliliter. BMD plates were
covered with the plastic covers provided with the BMD plates, stacked no more than 4 plates high, and
incubated at 35 to 37°C. Cefoxitin wells were read at 16 to 20 h, and oxacillin wells were read at 24 h.
PBP2 testing. Testing for PBP2a, which is encoded by mecA, was conducted using two immunoas-
says, namely, the PBP2a SA culture colony test (Abbott Diagnostics, Lake Forest, IL), which is a lateral flow
immunoassay, and the PBP2= latex agglutination test (Thermo Fisher Scientific), .following manufacturer
instructions. For the PBP2a SA culture colony test, instructions were followed as described for S. aureus,
which does not require overnight oxacillin induction. For the PBP2= latex agglutination test, the assay
was set up as recommended by the manufacturer following overnight oxacillin induction. For the latex
agglutination test and culture colony test, the recommended negative and positive S. aureus controls
were used, namely, ATCC 25923 (negative) and ATCC 43300 (positive), respectively.
Data analysis. MIC values for BMD experiments and DD zone diameters were read and recorded
systematically at 18 h and 24 h for test and control isolates to accommodate all breakpoints. Repeat
testing for mecA, PBP2a, and cefoxitin and oxacillin was conducted by the use of DD and BMD if the
oxacillin MIC and cefoxitin DD results were discrepant with regard to mecA status results, and the results
of the repeat testing were included for analysis. Zone diameters and MIC values were interpreted using
breakpoints and analysis time points for the following organisms: (i) S. aureus/S. lugdunensis; (ii) CoNS,
excluding S. lugdunensis, S. pseudintermedius, and S. schleiferi; and (iii) S. pseudintermedius and S. schleiferi
(Table 2) (CLSI M100-S28). Analysis was conducted on the MIC values collected at the following time
points as presented in the CLSI M100-S28 document (Table 2). For quality control (QC) strain S. aureus
ATCC 29213, S. aureus MIC value breakpoints were used to evaluate oxacillin MIC values at 24 h. For S.
epidermidis isolates, CoNS oxacillin MIC values were evaluated at 24 h and cefoxitin MIC values at 18 h.
For the QC strain S. aureus ATCC 25923, S. aureus cefoxitin zone diameters were measured at 24 h. For
S. epidermidis isolates, zone diameters were evaluated at 18 h for oxacillin and 24 h for cefoxitin.
Results were compared to those obtained using the gold standard method for determining resis-
tance to oxacillin, which was considered here to be the presence of mecA as determined by molecular
testing. Categorical agreement (CA), very major errors (VMEs), and major errors (MEs) were calculated as
follows: for CA, 100  ([number of isolates with categorical result matches]/[Total number of isolates
Identifying mecA-Mediated Resistance in S. epidermidis Journal of Clinical Microbiology
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tested]); for VME rate, 100  ([number of VMEs]/[total number of resistant isolates by reference method]);
for ME rate, 100  ([number of MEs]/[total number of susceptible isolates by reference method]).
Statistical calculations of 95% confidence intervals (CI) were performed using the Web-based MedCalc
statistical software.
RESULTS
Performance of cefoxitin DD. Results from cefoxitin DD testing are summarized in
Table 3 and Fig. 1A. The zones of inhibition showed a clear divide between mecA-
positive and -negative isolates across the 3 brands of media tested. This demarcation
coincides with the existing M100-S28 CoNS (excluding S. lugdunensis, S. pseudinterme-
dius, and S. schleiferi) breakpoint (Table 2) with 100% CA and no MEs or VMEs, indicating
that this breakpoint is appropriate for prediction of mecA status for S. epidermidis by the
use of cefoxitin DD. Upon application of the M100-S28 S. aureus/S. lugdunensis break-
points for cefoxitin DD testing, the CA ranged from 96% to 99% but the VMEs were
8.3% (4/48), 4.2% (2/48), and 2.1% (1/48) for the BD, Remel, and Hardy media, respec-
tively. The size distributions of zones of inhibition were similar across manufacturers
(see Table S1 in the supplemental material).
Performance of cefoxitin BMD. Cefoxitin BMD results are summarized in Table 3
and Fig. 1B. Three isolates (SEP052 [mecA positive; CHLA]; SEP072 [mecA negative;
CHLA] and SEP099 [mecA positive; BJH]) could not be assayed by BMD using media
from all 3 manufacturers due to absence of growth. All 3 isolates exhibited appropriate
growth on the associated purity plates. Cefoxitin BMD is not an approved method for
determining susceptibility to -lactams for CoNS, and the resultant MIC value distribu-
tions for S. epidermidis shows that the MIC values for mecA-positive and -negative
isolates overlap between 4 to 8 g/ml (Fig. 1B), which coincides with the M100-S28 S.
aureus/S. lugdunensis breakpoint for cefoxitin MIC (Table 2), thus supporting the
absence of cefoxitin BMD breakpoints for CoNS. Interpreting the cefoxitin MIC values
with the M100-S28 S. aureus/S. lugdunensis breakpoint, all CA-MHB media performed
similarly, with CA ranging from 95.9% to 96.9%. The distributions of MIC values were
similar across manufacturers (Table S2). The VME rates were 2.2% (1/46) for Difco and
4.3% (2/46) for both BBL and Oxoid. The ME rate was 3.9% (2/51) for all 3 brands of
CA-MHB.
Performance of oxacillin DD. Results from testing oxacillin DD are summarized in
Table 4 and Fig. 1C. One isolate (SEP099 [mecA positive; BJH]) failed to grow sufficiently
in the 16-to-18-h time range and was not included in the subsequent analysis; however,
it had sufficient growth at 24 h and was resistant to oxacillin and cefoxitin. At the time
of the study, oxacillin DD was recommended by CLSI as a method to detect mecA-
mediated -lactam resistance in S. pseudintermedius/S. schleiferi only (M100-S28). Zones
of inhibition read between 16 and 18 h after inoculation in this study showed a clear
demarcation between mecA-positive and -negative isolates, with a distribution along
the M100-S28 S. pseudintermedius/S. schleiferi oxacillin DD breakpoint (Fig. 1C). The
TABLE 2 CLSI M100-S28 breakpoints used at time of studya
Organism group









S R S R S R S R
S. aureus/S. lugdunensis 2 4 22 21 4 8
CoNS (except S. lugdunensis,
S. pseudintermedius,
S. schleiferi)
0.25 0.5 25 24
S. pseudintermedius/S. schleiferi 18 17 0.25 0.5
aCoNS, coagulase-negative Staphylococcus species; R, resistant; S, susceptible.
bThe organisms of the S. pseudintermedius/S. schleiferi group were incubated for 16 to 20 h prior to reading.
cThe organisms of all three groups were incubated for 24 h prior to reading.
dThe organisms of the S. aureus/S. lugdunensis group and the CoNS (except S. lugdunensis, S. pseudintermedius, S. schleiferi) group were incubated for 24 h prior to
reading.
eThe organisms of the S. aureus/S. lugdunensis group were incubated for 16 to 20 h prior to reading.
Naccache et al. Journal of Clinical Microbiology
December 2019 Volume 57 Issue 12 e00961-19 jcm.asm.org 4










































































































































































































































































































































































































































































































































































































































































































































Identifying mecA-Mediated Resistance in S. epidermidis Journal of Clinical Microbiology
December 2019 Volume 57 Issue 12 e00961-19 jcm.asm.org 5











majority (35/48, 72.9%) of mecA-positive isolates grew all the way to the edge of the
oxacillin disk (i.e., a zone size of 6 mm). Identical results were obtained for all three
brands of media with 100% CA and no VMEs or MEs, and the size distributions of zones
of inhibition were similar across manufacturers (Table S3). This indicates that for S.
FIG 1 Distribution of cefoxitin and oxacillin growth inhibition zones and MIC values as determined by DD
and BMD testing compiled for media from all three manufacturers. Breakpoints are derived from the CLSI
M100-S28 document. (A) Cefoxitin DD (BD) (Hardy and Remel media; n  300). The dotted line represents
the breakpoint for S. aureus and S. lugdunensis; the dashed line represents the breakpoint for CoNS
except S. lugdunensis, S. pseudintermedius, and S. schleiferi. (B) Cefoxitin BMD (Difco, BD, and Oxoid media;
n  291). The dotted line represents the breakpoint for S. aureus and S. lugdunensis. (C) Oxacillin DD (BD,
Hardy and Remel media; n  297). The dotted line represents the breakpoint for S. pseudintermedius and
S. schleiferi. (D) Oxacillin BMD (Difco, BD, and Oxoid media; n  291). The dotted line represents the
breakpoint for S. aureus and S. lugdunensis; the dashed line represents the breakpoint for CoNS except
S. lugdunensis, S. pseudintermedius, and S. schleiferi.
Naccache et al. Journal of Clinical Microbiology
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epidermidis, oxacillin DD is appropriate to predict mecA status using the M100-S28 S.
pseudintermedius/S. schleiferi breakpoints (Table 2).
Performance of oxacillin BMD. Results from tests of the oxacillin MIC are summa-
rized in Table 4 and Fig. 1D. Again, as with cefoxitin BMD testing, the same three
isolates (SEP052, SEP072, and SEP099) could not be assayed by BMD across all CA-MHB
media because they yielded no growth, despite growing on a BAP purity plate. MIC
value distributions revealed a clear separation between mecA-positive and -negative
isolates at between 0.25 and 0.5 g/ml (Fig. 1D). This is in agreement with the
M100-S28 CoNS breakpoints for oxacillin. Using CoNS breakpoints for oxacillin BMD
yielded 99% CA, 2% (1/51) MEs, and 0% (0/46) VMEs for all 3 CA-MHB brands.
Interpreted with the M100-S28 S. aureus/S. lugdunensis breakpoints, however, CA
dropped to 84.7% overall for Oxoid and 93.9% overall for Difco and BBL. The MEs were
consistent at 1/51 (2%) for all 3 CA-MHB brands, but the VMEs dramatically increased
to 14/46 (30.4%) for Oxoid and 5/46 (10.9%) for Difco and BBL. The distributions of MIC
values were similar across manufacturers (Table S4). Taken together, these data suggest
that oxacillin BMD continues to be an appropriate method for detecting mecA-
mediated -lactam resistance using the M100-S28 CoNS breakpoints (Table 2).
Performance of PBP2a immunoassays. PBP2a testing was performed on all iso-
lates using two immunoassays. The PBP2a SA culture colony test is approved by the U.S.
Food and Drug Administration (FDA) for detection of PBP2a in S. aureus only, but it
showed 100% agreement (100% sensitivity and specificity) with mecA as the gold
standard using the default manufacturer instructions. The PBP2= latex agglutination test
kit is indicated by the FDA for both S. aureus and CoNS, with a recommendation to
utilize overnight oxacillin induction for the latter. Using mecA as a gold standard, 2
mecA-positive isolates were miscategorized, resulting in overall sensitivity and speci-
ficity of 95.8% and 100%, respectively.
DISCUSSION
This study evaluated oxacillin and cefoxitin DD and BMD testing for the detection of
mecA-mediated -lactam resistance in 100 contemporary human S. epidermidis isolates
obtained from three geographical locations in the United States between 2015 and
2018. Nearly equal distributions of mecA-positive and -negative isolates were tested to
ensure even distributions of resistant and susceptible isolates. Data generated from
three MHA manufacturers (BD, Remel, and Hardy) and three CA-MHB manufacturers
(Difco, BD, and Oxoid) demonstrated that cefoxitin DD using CLSI M100-S28 CoNS
breakpoints and oxacillin DD using CLSI M100-S28 S. pseudintermedius/S. schleiferi
breakpoints accurately predicted the presence and absence of mecA in S. epidermidis
with 100% CA. Oxacillin BMD using CoNS breakpoints also yielded results that were
highly accurate (with only one false-positive isolate), resulting in a ME rate of 2% and
CA of 99%. While the zone of inhibition that was observed using Remel MHA was fainter
than that observed using the other two brands, as previously described (8), the zone
sizes were still readable and no notable differences in performance between all three
brands were identified.
A 2005 study of 310 CoNS isolates that included an undisclosed number of S.
epidermidis isolates supported the use of cefoxitin DD to predict the presence of mecA
in CoNS (10). Although there were four mecA-positive isolates of S. epidermidis that
were falsely classified as susceptible by cefoxitin DD, the errors were observed to be
related to media lot number or media brand rather than species-specific issues. An
important aspect of our study is the use of 100 contemporary and geographically
diverse isolates of S. epidermidis to confirm the reliability of cefoxitin DD in detecting
mecA-mediated -lactam resistance in S. epidermidis when CoNS breakpoints are used.
In contrast, cefoxitin DD failed to detect the presence of mecA in S. pseudintermedius
and S. schleiferi by the use of the M100-S27 breakpoints for CoNS, prompting the
removal of cefoxitin DD as an option for testing of S. pseudintermedius and S. schleiferi
isolates in the M100-S26 and M100-S28 documents, respectively (8, 9). This highlights
Naccache et al. Journal of Clinical Microbiology
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the need to critically evaluate other Staphylococcus species to determine the most
appropriate testing modalities.
As demonstrated here, oxacillin DD testing using breakpoints of 18 mm (suscep-
tible) and 17 mm (resistant) is reliable for predicting mecA-mediated -lactam resis-
tance in S. epidermidis, which is consistent with previous studies on S. pseudintermedius
(9) and S. schleiferi (8). Likewise, our data support the use of oxacillin BMD with the
CoNS (including S. pseudintermedius/S. schleiferi) breakpoints to accurately detect mecA-
mediated resistance in S. epidermidis. There are currently no cefoxitin MIC breakpoints
for non-S. aureus/S. lugdunensis species, and our data are consistent with those from
other studies that reported poor predictive value using S. aureus/S. lugdunensis cefoxi-
tin MIC breakpoints. Those studies reported very high VME rates of 89.2% and 60% for
S. pseudintermedius and S. schleiferi by the use of S. aureus/S. lugdunensis cefoxitin MIC
breakpoints, respectively, but no MEs were identified (8, 9). Although our finding of
3.6% VMEs for S. epidermidis is significantly lower than the rates reported from the
aforementioned studies, we also reported false-positive results for 6 isolates (ME rate of
3.9%).
The PBP2a SA culture colony test, which is approved by the FDA for PBP2a detection
in S. aureus, was 100% sensitive and 100% specific for S. epidermidis isolates by the use
of the default manufacturer instructions (i.e., without oxacillin induction). These find-
ings are consistent with other studies that reported 100% sensitivity and specificity for
other staphylococcal species, including 50 S. epidermidis (11) and 54 S. schleiferi (8)
isolates. Although the PBP2= latex agglutination test kit is FDA approved for both S.
aureus and CoNS (with oxacillin induction), two false negatives were identified, result-
ing in overall sensitivity and specificity of 95.8% and 100%, respectively. However,
previous studies reported sensitivity and specificity of 100% in testing S. epidermidis
isolates by the use of the PBP2= latex agglutination test kit after oxacillin induction (12,
13). We initially conducted a pilot testing without induction, but the results were
difficult to interpret, and all 100 S. epidermidis isolates were subsequently tested for
PBP2a using the PBP2= latex agglutination test kit with oxacillin induction. Likewise, a
previous study concluded that induction is necessary for successful detection of
oxacillin resistance in CoNS since testing without induction detected only 57.6% of
mecA-positive isolates (13).
In summary, our data demonstrate that oxacillin DD testing using the CLSI M100-S28
breakpoints for S. pseudintermedius/S. schleiferi can reliably differentiate between mecA-
positive and -negative S. epidermidis isolates. The results of testing using the break-
points for oxacillin BMD and cefoxitin DD for CoNS, other than S. lugdunensis, S.
pseudintermedius, and S. schleiferi, also showed high accuracy. Cefoxitin BMD testing
should not be used to predict mecA-mediated -lactam resistance in S. epidermidis due
to unacceptable false-positive and false-negative results. The findings from this study
were presented to the CLSI Antimicrobial Susceptibility Testing Subcommittee in June
2018, leading to the addition of specific breakpoints for oxacillin and cefoxitin DD and
oxacillin BMD testing for S. epidermidis in the 29th edition of the M100 document. The
CLSI Staphylococcus Ad Hoc Working Group will continue to systematically evaluate the
performance of current recommended phenotypic testing options for predicting mecA-
mediated -lactam resistance in other Staphylococcus species.
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